Navigation Links
Questcor to Commence Phase 2 Study of Acthar for ALS
Date:7/24/2013

ANAHEIM, Calif., July 24, 2013 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) announced today that patient screening will commence in connection with Questcor's Phase 2 Study to explore the safety and tolerability of H.P. Acthar® Gel (repository corticotropin injection) in patients with Amyotrophic Lateral Sclerosis (ALS).  ALS -- often referred to as Lou Gehrig's disease -- is a progressive, degenerative disease affecting motor neurons.  ALS is a serious debilitating disease that significantly alters one's quality of life.  According to the ALS Association, the average life expectancy from the time of diagnosis for someone affected by this disorder is about two to five years.

The study will seek to enroll up to 40 patients in an 8-week randomized, open-label trial designed to explore the safety and tolerability of four dosing regimens of Acthar.  Patients who successfully conclude the initial 8-week trial will then have the option to participate in a 28-week open-label extension with a 3-week taper and one week follow-up period.  The study will also examine whether Acthar provides any functional improvement to ALS patients.

"Questcor has focused its expanding R&D efforts on devastating medical conditions for which patients are in need of new treatment options," said Dr. David Young, Questcor's Chief Scientific Officer. " We are continually understanding more about the mechanism of action of Acthar and how it might provide benefit to patients in need.  Initial non-clinical research efforts provided us with data suggesting that Acthar may potentially provide therapeutic benefit to patients with ALS, leading us to conduct this important phase 2 study to further explore this possibility."

"In addition to this ALS trial, Questcor has on-going trials in idiopathic membranous nephropathy, systemic lupus erthymatosus, and diabetic nephropathy," continued Dr. Young. "These trials, combined with many mechanism of action studies and numerous Questcor-sponsored investigator initiated studies, are aimed at building the body of evidence surrounding the safety and efficacy of Acthar in both on-label and potential new indications."

For more information on studies related to Acthar, investors are encouraged to visit http://www.clinicaltrials.gov.

About ALS

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that affects nerve cells in the brain and the spinal cord. Motor neurons reach from the brain to the spinal cord and from the spinal cord to the muscles throughout the body. The progressive degeneration of the motor neurons in ALS eventually leads to their death. When the motor neurons die, the ability of the brain to initiate and control muscle movement is lost. With voluntary muscle action progressively affected, patients in the later stages of the disease may become totally paralyzed. The effect of this disease is not only a significant decrease in one's quality of life but also a decrease in life expectancy to an average of two to five years. At this time there is an unmet medical need for ALS treatments that significantly improve quality of life and/or extend survival.

ALS was first described in 1869 by French neurologist Jean-Martin Charcot, but it wasn't until 1939 that Lou Gehrig brought national and international attention to the disease when he abruptly retired from baseball after being diagnosed with ALS. Most commonly, the disease strikes people between the ages of 40 and 70, and as many as 30,000 Americans have the disease at any given time.

About Questcor                                                                                     

Questcor Pharmaceuticals, Inc. is a biopharmaceutical company focused on the treatment of patients with serious, difficult-to-treat autoimmune and inflammatory disorders. Questcor also provides specialty contract manufacturing services to the global pharmaceutical industry through its wholly-owned subsidiary BioVectra Inc. Questcor's primary product is H.P. Acthar® Gel (repository corticotropin injection), an injectable drug that is approved by the FDA for the treatment of 19 indications. Of its 19 FDA-approved indications, Questcor currently generates substantially all of its net sales from the following on-label indications: the treatment of proteinuria in the nephrotic syndrome of the idiopathic type, or NS, the treatment of acute exacerbations of multiple sclerosis, or MS, in adults, the treatment of infantile spasms, or IS, in infants and children under two years of age, and the treatment of certain rheumatology related conditions, including the treatment of the rare and closely related neuromuscular disorders dermatomyositis and polymyositis. With respect to nephrotic syndrome, the FDA has approved Acthar to "induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus." Questcor is also exploring the possibility of developing markets for other on-label indications and the possibility of pursuing FDA approval of additional indications not currently on the Acthar label where there is high unmet medical need such as ALS. Questcor also has agreed to acquire certain international rights for Synacthen® (tetracosactide) and Synacthen Depot®, and has licensed the right to develop and seek FDA approval for these products in the United States.  For more information about Questcor, please visit www.questcor.com.  For more information about Acthar, including important safety information, please visit www.acthar.com.

Note: Except for the historical information contained herein, this press release contains forward-looking statements that have been made pursuant to the Private Securities Litigation Reform Act of 1995. These statements relate to future events or our future financial performance. In some cases, you can identify forward-looking statements by terminology such as "believes," "continue," "could," "estimates," "expects," "growth," "intent," "may," "plans," "potential," "should," "substantial," "will," or "would" or the negative of such terms and other comparable terminology. These statements are only predictions. Actual events or results may differ materially. Factors that could cause or contribute to such differences include, but are not limited to, the following:

  • Research and development risks, including risks associated with Questcor's work in the area of ALS;
  • Our reliance on Acthar for substantially all of our net sales and profits;
  • The lack of patent protection for Acthar; and the possible FDA approval and market introduction of competitive products;
  • The results of any pending or future litigation, investigations or claims, including with respect to the investigation by the United States Attorney's Office for the Eastern District of Pennsylvania regarding the Company's promotional practices and litigation brought by certain shareholders arising from the federal securities laws, currently pending in the United States District Court for the Central District of California;
  • Our ability to effectively manage our growth, including the expansion of our sales forces, and our reliance on key personnel; and
  • Other risks discussed in Questcor's annual report on Form 10-K for the year ended December 31, 2012 as filed with the Securities and Exchange Commission, or SEC, on February 27, 2013, and other documents filed with the SEC.

The risk factors and other information contained in these documents should be considered in evaluating Questcor's prospects and future financial performance.

Questcor undertakes no obligation to publicly release the result of any revisions to these forward-looking statements, which may be made to reflect events or circumstances after the date of this release.

For more information, please visit www.questcor.com or www.acthar.com.


'/>"/>
SOURCE Questcor Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Questcor to Report Second Quarter Financial Results on July 30, 2013
2. Questcor to Initiate Pilot Commercialization Effort In Pulmonology for Symptomatic Sarcoidosis
3. Ongoing Clinical Trials Reveal Groundbreaking Results - Research Report on Alexion, BioMarin, Onyx, Questcor, and ImmunoGen
4. Questcor Adds Angus C. Russell to Board of Directors
5. Questcor Reports First Quarter Financial Results
6. Questcor to Report First Quarter Results on April 30, 2013
7. Questcor Reports Fourth Quarter and Full Year 2012 Results
8. Questcor to Report Fourth Quarter and Full Year 2012 Financial Results on February 26, 2013
9. Questcor Pharmaceuticals Appoints Michael Aldridge to the Position of Senior Vice President, Corporate Strategic Development
10. Questcor Pharmaceuticals Accelerates Cash Dividend; Payment Date Set for December 21, 2012
11. Harwood Feffer LLP Announces Investigation of Questcor Pharmaceuticals, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2017)... N.Y. , May 22, 2017  Lilac ... treatment Gene-Eden-VIR/Novirin, announces the launch of a ... English, the results of a clinical study that ... year treatment with Gene-Eden-VIR/Novirin in individuals suffering from ... to note that there are no other treatments ...
(Date:5/15/2017)... Enterin Inc., a privately-held CNS pharmaceutical company based in ... Parkinson,s disease (PD), has enrolled the first patient in the ... multicenter study involving patients with PD and taking place at ... 9-to-12-month period. The first stage is open label and involves ... include Denver , Boca Raton ...
(Date:5/10/2017)... -- The Corporate Whistleblower Center says, "We are urging ... to call us anytime at 866-714-6466 if they possess ... a substantial scheme to overbill Medicare. We are ... of a medical equipment company if their employer ... practice groups with extra generous incentives to use, or ...
Breaking Medicine Technology:
(Date:5/24/2017)... ... May 24, 2017 , ... If you are thinking of a visit to San ... architecture, October is the perfect time to visit. , Business Architecture Associates is pleased to ... offering for individuals, as a 4-½ day package for individuals, and as 4-½ day corporate ...
(Date:5/24/2017)... (PRWEB) , ... May 24, 2017 , ... ... most prominent for-profit and nonprofit hospitals and health systems in the nation and ... around their institutions, led professional organizations and been instrumental in developing successful hospital ...
(Date:5/24/2017)... ... May 24, 2017 , ... Dymedix® Diagnostics, ... sensors, announced today it had completed the first phase of building a global ... and rest of world (ROW) authorized dealers specializing in polysomnography accessories. The ...
(Date:5/23/2017)... ... May 23, 2017 , ... Allegheny Health Network and ... Joy D’Achille Center for Women’s Behavioral Health at West Penn Hospital , a ... for women suffering from pregnancy-related depression. Construction of the Center is underway with ...
(Date:5/23/2017)... ... 23, 2017 , ... New England Journal Of Medicine Confirms Viability of Rory’s ... -The Rory Staunton Foundation Calls on Health & Human Services, Tom Price to Adopt ... http://www.rorystauntonfoundation.org ) today reported on a new study released on May 21, 2017 in ...
Breaking Medicine News(10 mins):